The management of biliary tract cancer (BTC) has deeply changed in the past decade. Just few years ago patients with advanced disease had no effective treatment options but supportive therapy. Palliative chemotherapy was often administered in the absence of evidence of efficacy, as no randomized studies were available.
Targeted agents: how can we improve the outcome in biliary tract cancer?
AGLIETTA, Massimo;LEONE, Francesco
2013-01-01
Abstract
The management of biliary tract cancer (BTC) has deeply changed in the past decade. Just few years ago patients with advanced disease had no effective treatment options but supportive therapy. Palliative chemotherapy was often administered in the absence of evidence of efficacy, as no randomized studies were available.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Hepatobiliary Surg Nutr. 2013_Marino D et al.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
257.63 kB
Formato
Adobe PDF
|
257.63 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
